In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page
Risk Minimisation Activities: clarifications on Circular No. 635

Risk Minimisation Activities: clarifications on Circular No. 635

by In2Pharma | Feb 26, 2021 | News

Belgium Circular No. 635 (4 May 2018) details the approval procedure for risk minimisation activities (RMA). Certain paragraphs of this circular could be misinterpreted and specific situations were not considered. Therefore, the FAMHP provided more...

Recent Posts

  • Medical devices – turnover declaration
  • Update instructions for distribution of DHPC in Luxembourg
  • Diploma for the Responsible Person for Information and Publicity (RIP)
  • Update Procedure for MA applications in Luxembourg
  • Labeling Medicinal products

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België